ClinicaliQ Trial Snapshot
- A Study Evaluating Different Immunotherapies (LAG-3 and PD-1 With or Without TIGIT, Compared to PD-L1 Alone) in Participants With Untreated Locally Advanced Metastatic Urothelial Cancer — Active Not Recruiting • Phase II • Oncology • NCT05645692.
- Three immunotherapy combinations tested in chemotherapy-ineligible patients with advanced bladder cancer: LAG-3 alone, LAG-3 plus TIGIT inhibitor, versus PD-L1 inhibitor.
Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
This study will evaluate the safety of tobemstomig alone or in combination with tiragolumab compared with atezolizumab in participants with previously untreated, locally advanced or metastatic urothelial cancer (mUC) who are ineligible to receive a platinum containing chemotherapy. Conditions: Urothelial Cancer Interventions: Atezolizumab, Tobemstomig, Tiragolumab Lead Sponsor: Hoffmann-La Roche Planned Enrollment: 204 participants